Wall Street’s New Tariff Safe Haven: High-Tax Biotech Stocks - WSJ
1. Gilead and Vertex outperform due to strong U.S. manufacturing focus. 2. Higher corporate tax rates now seen as beneficial amid looming tariffs. 3. Trump administration targeting pharma imports to incentivize U.S. manufacturing. 4. Gilead's upcoming lenacapavir launch aligns with industry growth expectations. 5. Industry-wide analysis estimates a potential 9.7% hit to operating income.